{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:36:02Z","timestamp":1782502562405,"version":"3.54.5"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"crossref","award":["APP1140503"],"award-info":[{"award-number":["APP1140503"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,28]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>We compared weight changes in virally suppressed people living with HIV (PLWH) switching to integrase strand transfer inhibitors (INSTIs) with those remaining on an INSTI or non-INSTI regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PLWH aged \u226518\u2005years with weight measurements available at baseline between 2001 and 2020 were included. Viral suppression was defined as having had a viral load &amp;lt;400\u2005copies\/mL for 6\u2005months. Baseline was defined as the time of switching from a non-INSTI to an INSTI regimen whilst virally suppressed (switch group) or the time that viral suppression was achieved (remain groups). Generalized estimating equations adjusted for age, sex and baseline weight were used to model weight changes 6, 12, 18 and 24\u2005months after baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1673 PLWH contributed 1952 episodes of viral suppression\u2014143 (7.3%) episodes were among PLWH who had switched from a non-INSTI to an INSTI, 102 (5.2%) episodes were among PLWH who remained on an INSTI and 1707 (87.4%) episodes were among PLWH who remained on a non-INSTI. PLWH in the switch group had significantly greater weight gain than those in the remain groups at 6, 12 and 18\u2005months after achieving viral suppression. By 24\u2005months, weight change on all regimens started to converge. Tenofovir alafenamide use was not significantly associated with weight gain in adjusted models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our findings suggest that the mechanisms of weight gain due to INSTI use go beyond their superior efficacy over other antiretrovirals in controlling HIV or the effect of the \u2018return-to-health\u2019 phenomenon. Further research is needed to understand the mechanisms of such weight gain.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkac306","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T05:33:54Z","timestamp":1663133634000},"page":"3242-3247","source":"Crossref","is-referenced-by-count":5,"title":["Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-7960","authenticated-orcid":false,"given":"Win Min","family":"Han","sequence":"first","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS Research Centre , Bangkok 10330 , Thailand"},{"name":"The Kirby Institute, UNSW Sydney , Sydney 2052 , Australia"},{"name":"Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok 10330 , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Kerr","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS Research Centre , Bangkok 10330 , Thailand"},{"name":"The Kirby Institute, UNSW Sydney , Sydney 2052 , Australia"},{"name":"Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok 10330 , Thailand"},{"name":"Biostatistics Excellence Centre, Faculty of Medicine, Chulalongkorn University , Bangkok 10330 , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS Research Centre , Bangkok 10330 , Thailand"},{"name":"Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok 10330 , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Boettiger","sequence":"additional","affiliation":[{"name":"The Kirby Institute, UNSW Sydney , Sydney 2052 , Australia"},{"name":"Biostatistics Excellence Centre, Faculty of Medicine, Chulalongkorn University , Bangkok 10330 , Thailand"},{"name":"Institute for Health and Aging, University of California , San Francisco, CA 94102 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"2022112816501009100_dkac306-B1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"2022112816501009100_dkac306-B2","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(13)70271-8","article-title":"Metabolic disease in HIV infection","volume":"13","author":"Lake","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2022112816501009100_dkac306-B3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/QAD.0b013e32832913ee","article-title":"Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries","volume":"23","author":"Madec","year":"2009","journal-title":"AIDS"},{"key":"2022112816501009100_dkac306-B4","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/cid\/civ192","article-title":"Weight change after antiretroviral therapy and mortality","volume":"60","author":"Yuh","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022112816501009100_dkac306-B5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022112816501009100_dkac306-B6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/QAI.0000000000001071","article-title":"Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals","volume":"73","author":"Herrin","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022112816501009100_dkac306-B7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","article-title":"Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens","volume":"76","author":"Norwood","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022112816501009100_dkac306-B8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2022112816501009100_dkac306-B9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cts.12771","article-title":"Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications","volume":"13","author":"Lo","year":"2020","journal-title":"Clin Transl Sci"},{"key":"2022112816501009100_dkac306-B10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QAD.0000000000002379","article-title":"No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV","volume":"34","author":"Burns","year":"2020","journal-title":"AIDS"},{"key":"2022112816501009100_dkac306-B11","doi-asserted-by":"crossref","first-page":"ofx239","DOI":"10.1093\/ofid\/ofx239","article-title":"Weight gain: a possible side effect of all antiretrovirals","volume":"4","author":"Taramasso","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2022112816501009100_dkac306-B12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022112816501009100_dkac306-B13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2021.07.030","article-title":"Long-term weight gain after initiating combination antiretroviral therapy in treatment-na\u00efve Asian people living with human immunodeficiency virus","volume":"110","author":"Ando","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2022112816501009100_dkac306-B14","doi-asserted-by":"crossref","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","article-title":"Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy","volume":"71","author":"Lake","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022112816501009100_dkac306-B15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7326\/M17-2242","article-title":"HIV Viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study","volume":"169","author":"Nance","year":"2018","journal-title":"Ann Intern Med"},{"key":"2022112816501009100_dkac306-B16","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2022112816501009100_dkac306-B17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/QAI.0000000000002556","article-title":"Brief report: weight gain following ART initiation in ART-na\u00efve people living with HIV in the current treatment era","volume":"86","author":"Ruderman","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022112816501009100_dkac306-B18","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022112816501009100_dkac306-B19","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/cid\/ciab444","article-title":"Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials","volume":"73","author":"Erlandson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022112816501009100_dkac306-B20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fendo.2018.00705","article-title":"The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022112816501009100_dkac306-B21","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3018(21)00163-6","article-title":"Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium","volume":"8","author":"Bansi-Matharu","year":"2021","journal-title":"Lancet HIV"},{"key":"2022112816501009100_dkac306-B22","doi-asserted-by":"crossref","first-page":"ofab542","DOI":"10.1093\/ofid\/ofab542","article-title":"Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter?","volume":"8","author":"Wood","year":"2021","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/12\/3242\/47369621\/dkac306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/12\/3242\/47369621\/dkac306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T06:20:26Z","timestamp":1700979626000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/12\/3242\/6697017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,9,14]]},"published-print":{"date-parts":[[2022,11,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac306","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,9,14]]}}}